The Ewing Sarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ewing Sarcoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued products.

GlobalData tracks 97 drugs in development for Ewing Sarcoma by 92 companies/universities/institutes. The top development phase for Ewing Sarcoma is preclinical with 36 drugs in that stage. The Ewing Sarcoma pipeline has 86 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Ewing Sarcoma pipeline products market are: Pharma Mar, Eisai and Pfizer.

The key targets in the Ewing Sarcoma pipeline products market include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1), and Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1).

The key mechanisms of action in the Ewing Sarcoma pipeline product include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Inhibitor with six drugs in Phase II. The Ewing Sarcoma pipeline products include 16 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Ewing Sarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.

Ewing Sarcoma overview

Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

For a complete picture of Ewing Sarcoma’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.